Some choose off-label drug to treat macular degeneration

09/22/2006 | Miami Herald (free registration), The

While a new drug called Lucentis has been approved by the FDA to restore vision to people with macular degeneration, many doctors are using a similar drug, Avastin, off-label. That's because Avastin costs only about $50 per dose and Lucentis costs about $2,000 per injection.

View Full Article in:

Miami Herald (free registration), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX